Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction - PubMed
5 hours ago
- #anti-VEGF therapy
- #cardiovascular events
- #retrospective cohort study
- The study evaluated the systemic safety of continuing intravitreal anti-VEGF therapy around the time of cardiovascular events (CVE), such as stroke or myocardial infarction (MI).
- A retrospective cohort analysis of electronic health records used propensity score matching to compare patients who received anti-VEGF injections within a peri-CVE window versus those who did not.
- Peri-CVE anti-VEGF was associated with lower mortality at 3 months and 1 year for both stroke and MI patients, and reduced short-term complications like neurologic deficits after stroke and heart failure after MI.
- Sensitivity analyses restricting the exposure window showed similar mortality benefits without significant differences in other outcomes.
- No differences in outcomes were observed among the specific anti-VEGF agents (aflibercept, bevacizumab, ranibizumab), supporting the safety of continuing therapy without modification during the peri-CVE period.